Pyxis Oncology sells royalty rights to Novartis for $8M upfront cash

Pyxis Oncology, Inc.

One-time $8M payment from Novartis for rights to Beovu and another asset royalties.
All prior royalties from Apexigen and Pyxis Oncology are free from reclaim.
Non-dilutive capital to support lead ADC asset PYX-201 development.
Pyxis retains rights to three other antibodies from Apexigen licensees.
$8M payment to be recorded in Q1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.